WO2013177291A1 - Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof - Google Patents
Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof Download PDFInfo
- Publication number
- WO2013177291A1 WO2013177291A1 PCT/US2013/042240 US2013042240W WO2013177291A1 WO 2013177291 A1 WO2013177291 A1 WO 2013177291A1 US 2013042240 W US2013042240 W US 2013042240W WO 2013177291 A1 WO2013177291 A1 WO 2013177291A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- plasmid
- acid molecule
- sequence
- fusion protein
- Prior art date
Links
- 241000607479 Yersinia pestis Species 0.000 title claims abstract description 95
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 title claims abstract description 52
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 48
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 48
- 239000013612 plasmid Substances 0.000 claims abstract description 80
- 206010035148 Plague Diseases 0.000 claims abstract description 69
- 108091026890 Coding region Proteins 0.000 claims abstract description 41
- 230000028327 secretion Effects 0.000 claims abstract description 40
- 241000588724 Escherichia coli Species 0.000 claims abstract description 37
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 33
- 101150018266 degP gene Proteins 0.000 claims abstract 3
- 101150007310 htrA gene Proteins 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 81
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 230000002163 immunogen Effects 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 abstract description 9
- 229940126578 oral vaccine Drugs 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 31
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 14
- 101710194807 Protective antigen Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 201000006824 bubonic plague Diseases 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 201000009430 pneumonic plague Diseases 0.000 description 10
- 206010058889 Plague sepsis Diseases 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 201000008011 septicemic plague Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000193738 Bacillus anthracis Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229960000268 spectinomycin Drugs 0.000 description 4
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 206010003399 Arthropod bite Diseases 0.000 description 3
- 241001415830 Bubo Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 206010065224 Lymphadenitis bacterial Diseases 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241001138501 Salmonella enterica Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- -1 TNF- Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000191823 Cynomys Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 229940124857 Salmonella typhi vaccine Drugs 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010008681 Type II Secretion Systems Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960004545 plague vaccines Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000012810 sudden onset of fever Diseases 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/402,457 US9409956B2 (en) | 2012-05-23 | 2013-05-22 | Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof |
IN9618DEN2014 IN2014DN09618A (en) | 2012-05-23 | 2013-05-22 | |
JP2015514155A JP6216371B2 (en) | 2012-05-23 | 2013-05-22 | Salmonella TyphiTy21a expressing Yersinia pestis F1-V fusion protein and uses thereof |
EP13726394.3A EP2852405B1 (en) | 2012-05-23 | 2013-05-22 | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
CN201380038155.8A CN104470537B (en) | 2012-05-23 | 2013-05-22 | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
IL235615A IL235615A0 (en) | 2012-05-23 | 2014-11-10 | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650676P | 2012-05-23 | 2012-05-23 | |
US61/650,676 | 2012-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013177291A1 true WO2013177291A1 (en) | 2013-11-28 |
WO2013177291A8 WO2013177291A8 (en) | 2014-12-24 |
Family
ID=48539444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/042240 WO2013177291A1 (en) | 2012-05-23 | 2013-05-22 | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US9409956B2 (en) |
EP (1) | EP2852405B1 (en) |
JP (1) | JP6216371B2 (en) |
CN (1) | CN104470537B (en) |
IL (1) | IL235615A0 (en) |
IN (1) | IN2014DN09618A (en) |
WO (1) | WO2013177291A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10806778B2 (en) * | 2019-01-30 | 2020-10-20 | Prokarium Limited | Modified strain of Salmonella enterica Typhi |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856935A (en) | 1971-04-29 | 1974-12-24 | Schweiz Serum & Impfinst | Oral typhoid vaccine and method of preparing the same |
WO1996028551A1 (en) * | 1995-03-13 | 1996-09-19 | The Secretary Of State For Defence | Vaccines for plague |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7758855B2 (en) | 2003-09-18 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA promoters and anthrax vaccines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9326425D0 (en) | 1993-12-24 | 1994-02-23 | Secr Defence | Vaccine compositions |
WO2000014240A2 (en) * | 1998-09-04 | 2000-03-16 | Creatogen Aktiengesellschaft | Attenuated salmonella sp12 mutants as antigen carriers |
GB9921275D0 (en) * | 1999-09-10 | 1999-11-10 | Secr Defence | Recombinant microorganisms |
AU2004296394A1 (en) * | 2003-12-09 | 2005-06-23 | Avant Immunotherapeutics, Inc. | Orally-administered live bacterial vaccines for plague |
US20080124355A1 (en) * | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
-
2013
- 2013-05-22 CN CN201380038155.8A patent/CN104470537B/en not_active Expired - Fee Related
- 2013-05-22 US US14/402,457 patent/US9409956B2/en active Active
- 2013-05-22 WO PCT/US2013/042240 patent/WO2013177291A1/en active Application Filing
- 2013-05-22 EP EP13726394.3A patent/EP2852405B1/en not_active Not-in-force
- 2013-05-22 IN IN9618DEN2014 patent/IN2014DN09618A/en unknown
- 2013-05-22 JP JP2015514155A patent/JP6216371B2/en not_active Expired - Fee Related
-
2014
- 2014-11-10 IL IL235615A patent/IL235615A0/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856935A (en) | 1971-04-29 | 1974-12-24 | Schweiz Serum & Impfinst | Oral typhoid vaccine and method of preparing the same |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1996028551A1 (en) * | 1995-03-13 | 1996-09-19 | The Secretary Of State For Defence | Vaccines for plague |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US7758855B2 (en) | 2003-09-18 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA promoters and anthrax vaccines |
Non-Patent Citations (32)
Title |
---|
"Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC. |
"The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD. |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL, NATURE GENET, vol. 6, 1994, pages 119 - 129 |
BENJAMIN LEWIN: "Genes V", 1994, OXFORD UNIVERSITY PRESS |
BITTER, METHODS IN ENZYMOLOGY, vol. 153, 1987, pages 516 - 544 |
CAO ET AL., STEM CELLS, vol. 16, no. 1, 1998, pages 251 - 60 |
CORPET ET AL., NUCLEIC ACIDS RESEARCH, vol. 16, 1988, pages 10881 - 10890 |
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO. |
GERMANIER; FURER, J INFECT DIS, vol. 131, 1975, pages 553 - 558 |
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151 - 153 |
HIGGINS; SHARP, GENE, vol. 73, 1988, pages 237 - 244 |
KUIPER ET AL., ADV. 1!-'XP. MED. BIOL., vol. 465, 2000, pages 381 - 90 |
LEARY ET AL., MICROB PATHOG, vol. 23, 1997, pages 167 - 179 |
LEARY SOPHIE E C ET AL: "Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague", MICROBIAL PATHOGENESIS, vol. 23, no. 3, 1997, pages 167 - 179, XP002713061, ISSN: 0882-4010 * |
LEARY, MICROB PATHOG, vol. 23, 1997, pages 167 - 179 |
LOTZE ET AL., CANCER J. SCI. AM., vol. 6, no. 1, 2000, pages 61 - 6 |
MORTON ET AL., VACCINE, vol. 22, 2004, pages 2524 - 2532 |
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
OSORIO ET AL., INFECT IMMUN, vol. 77, no. 4, 2009, pages 1475 - 1482 |
OSORIO MANUEL ET AL: "Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.", INFECTION AND IMMUNITY APR 2009, vol. 77, no. 4, April 2009 (2009-04-01), pages 1475 - 1482, XP055054973, ISSN: 1098-5522 * |
OSORIO, INFECT IMMUN, vol. 77, no. 4, 2009, pages 1475 - 1482 |
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444 |
SALGALLER ET AL., J. SURG. ONCOL., vol. 68, no. 2, 1998, pages 122 - 38 |
SIZEMORE DONATA R ET AL: "Construction and screening of attenuated [Delta]phoP/Q Salmonella typhimurium vectored plague vaccine candidates", HUMAN VACCINES & IMMUNOTHERAPEUTICS 1 NOV 2012,, vol. 8, no. 3, 1 March 2012 (2012-03-01), pages 371 - 383, XP009172541, ISSN: 2164-554X, DOI: 10.4161/HV.18670 * |
SMITH; WATENNAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 |
SUN ET AL., J INFECT DEV CTRIES, vol. 5, no. 9, 2011, pages 614 - 627 |
SUN, J INFECT DEV CTRIES, vol. 5, no. 9, 2011, pages 614 - 627 |
WAHDAN ET AL., BULL WHO, vol. 58, 1980, pages 469 - 474 |
XU ET AL., INFECT IMMUN, vol. 70, no. 8, 2002, pages 4414 - 4423 |
YANG ET AL., J IMMUNOL, vol. 178, 2007, pages 1059 - 1067 |
YANG, JLMMUNOL, vol. 178, 2007, pages 1059 - 1067 |
Also Published As
Publication number | Publication date |
---|---|
JP2015519061A (en) | 2015-07-09 |
EP2852405B1 (en) | 2019-03-13 |
EP2852405A1 (en) | 2015-04-01 |
IL235615A0 (en) | 2015-01-29 |
IN2014DN09618A (en) | 2015-07-31 |
US20150152144A1 (en) | 2015-06-04 |
US9409956B2 (en) | 2016-08-09 |
CN104470537A (en) | 2015-03-25 |
CN104470537B (en) | 2017-04-26 |
JP6216371B2 (en) | 2017-10-18 |
WO2013177291A8 (en) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pasquevich et al. | The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis | |
ES2328751T3 (en) | RELEASE OF BIOLOGICALLY ACTIVE POLYPEPTIDES. | |
CN106102768B (en) | Mycobacterial antigen compositions | |
Wolfenden et al. | Development and evaluation of candidate recombinant Salmonella-vectored Salmonella vaccines | |
US20230090746A1 (en) | Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori | |
BRPI1003750A2 (en) | recombinant microorganisms, methods of preparation of vaccine strains, antigens, vectorized vaccine compositions, their uses, antibodies, diagnostic kit and methods of treatment and / or prophylaxis | |
Won et al. | Multifaceted immune responses and protective efficacy elicited by a recombinant autolyzed Salmonella expressing FliC flagellar antigen of F18+ Escherichia coli | |
KR101743442B1 (en) | Vaccine composition for preventing or treating porcine edema disease comprising ghost Salmonella mutant expressing Enterotoxigenic Escherichia coli antigen as effective component | |
US9409956B2 (en) | Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof | |
Yunle et al. | Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review | |
Senevirathne et al. | Intranasally administered anti-Brucella subunit vaccine formulation induces protective immune responses against nasal Brucella challenge | |
US20110033492A1 (en) | Vaccines for brucellosis | |
Liu et al. | Oral immunization of mice with attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit | |
Won et al. | Potent immune responses induced by a Salmonella ghost delivery system that expresses the recombinant Stx2eB, FedF, and FedA proteins of the Escherichia coli-producing F18 and Shiga toxin in a murine model and evaluation of its protective effect as a porcine vaccine candidate | |
Jeon et al. | Attenuated Salmonella Gallinarum secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for oral vaccination against fowl typhoid | |
IL299546A (en) | A dna plasmid sars-coronavirus-2/covid-19 vaccine | |
US20150238590A1 (en) | Use of the salmonella spp type iii secretion proteins as a protective vaccination | |
JP2023503057A (en) | A novel vaccine against Haemophilus parasuis | |
JP2023503058A (en) | A novel vaccine against Haemophilus parasuis | |
US10406219B2 (en) | Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same | |
Mobed | DNA Based vaccines against Mycobacterium tuberculosis: recent progress in vaccine development and delivery system | |
CN101896196A (en) | Structure is used for the DNA chimera of leishmaniasis and vaccine development lungy | |
Byeon et al. | Generation of an attenuated Salmonella-delivery strains expressing adhesin and toxin antigens for progressive atrophic rhinitis, and evaluation of its immune responses in a murine model | |
US20190216911A1 (en) | Recombinant eimeria maxima protein delivered as nanoparticles | |
Chuekwon et al. | Immune Response to the Dual Antigen Vaccine of Actinobacillus pleuropneumoniae in a Mouse Model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13726394 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 235615 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015514155 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14402457 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013726394 Country of ref document: EP |